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cense. httpAbstract Introduction: Breast cancer (BC) is a major health problem in Egypt and worldwide. Its
prognosis depends not only on tumor stage but also on tumor biology.
Aim: To correlate the expression of Ki67 with the clinical outcomes of early hormone-receptor
positive postmenopausal BC patients who are receiving tamoxifen.
Methods: This cohort study included 70 patients. Theywere followed up for aminimumof 2 years. Ki67
was assessed on parafﬁn-embedded blocks using immunohistochemistry methods.
Results: The median Ki67 value was 22.5% (IQR, 10%–50%). Ki67 was signiﬁcantly higher in patients
with HER2 positive tumors compared to HER2 negative tumors. After a median follow up period of
53 months, 22 patients (31%) developed disease recurrence either loco-regional or distant in 5.7% and
30%, respectively.Recurrentpatientshadsigniﬁcantlyhigher tumor stage, nodal stageandKi67values com-
pared tonon-recurrent cases.The2-, 3- and5-yearoverall survival (OS) anddisease-free survival (DFS) rates
were 100% & 91%, 98% & 84% and 77% & 59%, respectively. DFS was signiﬁcantly worse with higher
TNM stage, lower ER expression and higher Ki67 values. OS was signiﬁcantly worse in patients with
Ki67 valuesP30%. Ki67P30% was an independent predictor of recurrence, poor DFS and OS.
Conclusion: HighKi67 expression is predictive of poor prognosis and of resistance to adjuvant tamoxifen
therapy in postmenopausal BC. We recommend considering Ki67 as one of the risk factors that guide
adjuvant treatment decisions.
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Breast cancer (BC) is the most common female malignancy
accounting for 22.9% and 37.7% of all female cancers world-
wide and in Egypt, respectively [1]. These estimates are con-
ﬁrmed in many regional Egyptian cancer registries [2,3] as
well as in hospital-based frequencies [4]. BC is also the leading
cause of cancer death in females accounting for 13.7% ofational Cancer Institute, Cairo University.
.001
182 H.M. Elzawahry et al.female cancer-related mortality globally compared to 29.1% in
Egypt. Incidence to mortality ratio of BC in Egypt is poor
(1.9:1) compared to a more favorable global ratio (3.7:1) [1].
In developed countries, around 65% of all BC occurs in
postmenopausal women, of which about 80% are hormone
receptor-positive [5,6]. In Egypt, 51% of breast cancers occur
in postmenopausal women of whom 60% are hormone recep-
tor-positive [7]. The anti-estrogen tamoxifen is the drug most
often used for the long-term treatment of early breast cancer
[8]. Tumor recurrence and mortality are signiﬁcantly decreased
by the use of 5 years of adjuvant tamoxifen both in the pres-
ence and absence of adjuvant chemotherapy [9]. However, a
serious limitation of tamoxifen is the inevitable appearance
of resistance; either de novo or acquired [8]. Approximately
40% of the patients receiving adjuvant tamoxifen therapy
experience tumor relapse and die from their disease [10]. The
yearly recurrence rates remain above 2% for a long period
and more than 30% of women develop recurrent disease with-
in 15 years [9].
Tamoxifen competes with estrogen for estrogen receptors
(ERs) leading to conformational changes that prevent binding
of co-activators and blocks activating function-1 (AF-1) do-
main [10]. The proposed mechanisms of tamoxifen resistance
are diverse and include: Loss of ERa expression/function
[11], altered expression of ERb [12], lack of PR expression
[13], alterations in co-regulatory proteins [14], decreased cellu-
lar inﬂux or increased efﬂux [15], pharmacogenetic effects par-
ticularly those involving CYP2D6 or cross talk between ER
and other signal transduction pathways [16].
Ki67 is a nuclear protein expressed during cellular prolifer-
ation particularly during the mitosis phase [17]. In early BC,
high Ki67 is an independent factor for worse prognosis as
shown by signiﬁcantly shorter overall and disease-free survival
[18,19]. High Ki67 was predictive of more beneﬁt from adju-
vant letrozole over tamoxifen [20] and adjuvant taxane over
non-taxane regimens [21,22]. On the other hand, Ki67 was
not predictive of more beneﬁt of adjuvant chemoendocrine
therapy over endocrine therapy alone [23] or adjuvant epirubi-
cin-CMF over CMF [24].
The aim of the current study was to correlate the expression
of ki67 with the clinical outcomes of early hormone-receptor
positive postmenopausal breast cancer patients who are receiv-
ing adjuvant tamoxifen.
Methods
Design and setting
This was a prospective cohort study conducted in the Medical
Oncology Department, National Cancer Institute, Cairo Uni-
versity (NCI-Egypt) between July 2007 and March 2012. The
study was conducted in compliance with Good Clinical Prac-
tice guidelines and the ethical principles routed in the Declara-
tion of Helsinki. The study was approved by the Institutional
Review Board of NCI-Egypt.
Eligibility
Patients were included in the study if they were postmeno-
pausal females, had histologically conﬁrmed BC, had hormone
receptors’ positive (HR) tumors (i.e. positive for estrogenreceptors [ER] and/or progesterone receptors [PR]), undergone
curative surgery, and were receiving adjuvant tamoxifen. Pa-
tients were excluded if they were males or premenopausal fe-
males, negative for ER and PR, or receiving aromatase
inhibitors. Sampling was consecutive.
Immunohistochemistry (IHC) studies and their interpretation
Formalin-ﬁxed parafﬁn-embedded blocks of all patients were
obtained from the pathology department of NCI-Egypt for
IHC study. One 4-lm section of each submitted parafﬁn block
was ﬁrst stained with Hematoxylin and Eosin to verify that an
adequate number of invasive carcinoma cells were present, and
the ﬁxation quality was sufﬁcient for IHC analysis. ER & PR
were evaluated using Monoclonal Antibody, Ready-to-Use
(Cell Marque, USA). HER2 was evaluated by using Mouse
Monoclonal Antibody, Ready-to-Use (Clone e2-4001+3B5,
Cat.#MS-730-R7, Thermo Scientiﬁc, USA). Ki67 was evalu-
ated using Rabbit Polyclonal Antibody, Ready-to-Use
(Cat.#RB-9043-R7, Thermo Scientiﬁc, USA). p53 was evalu-
ated by using a Mouse Monoclonal Antibody, Ready-to-Use
(DO7, Cat.#453M-98, Cell Marque, USA). The universal kit
used was Anti-Polyvalent, HRP/DAB, Ready-to-Use
(Cat.#TP-015-HD, Thermo Scientiﬁc, USA).
According to recommendations of the American Society
of Clinical Oncology/College of American Pathologists
(ASCO/CAP), ER and PR were considered positive for
expression when P1% of the cell nuclei stain with the anti-
body [25]. Interpretation of HER2 was also according to the
recommendations of ASCO/CAP with a positive HER2 re-
sult being IHC staining of 3+ (uniform, intense membrane
staining of >30% of invasive tumor cells) [26]. According to
the recommendations of the International ki67 in Breast
Cancer Work group, the Ki67 score was deﬁned as the per-
centage of total number of tumor cells with nuclear staining
by the antibody [27]. Ki67 was regarded as overexpressed at
score P14% [28]. p53 expression was determined by the per-
centage of total number of tumor cells with nuclear staining
by the antibody & was regarded as accumulated (positive
for overexpression) when P5% of nuclei were stained,
whereas values <5% were regarded as negative for muta-
tion [29].
Statistical issues
All analyses were done using SPSS (Statistical Package for
Social Sciences) software, version 17, Chicago, USA. Numeri-
cal values were expressed as means or medians and standard
deviation (SD) or range. Survival was estimated using prod-
uct-limit methods. Curves were compared using log rank test.
Correlations between numerical variables were assessed using
the Pearson’s correlation method. Cox regression analysis de-
picted independent covariates on different disease outcomes.
To be included in the regression analysis, a variable should
have a p value 60.1. Proportions were tested for independence
using the Chi-square and Fisher exact tests. A receiver opera-
tor characteristic (ROC) curve was the tool used to select a cut-
off point for ki67 as a continuous variable. P value was set sig-
niﬁcant at 60.05 level. The primary endpoint was disease free-
survival (DFS). The secondary endpoint was overall survival
(OS).
Table 1 Patients’ characteristics of 70 postmenopausal breast cancer patients receiving adjuvant tamoxifen and the corresponding
Ki67 expression.
Characteristics All patients Ki67 <14%
no. (%)
Ki P14%
no. (%)
p Ki67 <30%
no. (%)
Ki P30%
no. (%)
p
Total 70 (100) 27 (38.6) 43 (61.4) 37 (52.9) 33 (47.1)
Age in years Mean ± SD 60 ± 5.0 61 ± 4.0 61 ± 5.0 0.99 61 ± 5.0 60 ± 4.0 0.98
Histology IDC 62 (88.6) 24 (88.9) 38 (88.3) 32 (86.5) 30 (90.9)
ILC 5 (7.1) 2 (7.4) 3 (7.0) 3 (8.1) 2 (6.1)
Mixed 3 (4.3) 1 (3.7) 2 (4.7) 0.98 2 (5.4) 1 (3.0) 0.83
Grade NA 5 (7.1) 2 (7.4) 3 (7.0) 3 (8.1) 2 (6.1)
IDC GII 59 (84.3) 22 (81.5) 37 (86.0) 30 (81.1) 29 (87.8)
IDC GIII 6 (8.6) 3 (11.1) 3 (7.0) 0.83 4 (10.8) 2 (6.1) 0.72
T stage T1 13 (18.6) 3 (11.1) 10 (32.3) 6 (16.2) 7 (21.2)
T2 38 (54.3) 17 (63.0) 21 (48.8) 21 (56.8) 17 (51.5)
T3 9 (12.9) 4 (14.8) 5 (11.6) 6 (16.2) 3 (9.1)
T4b 10 (14.3) 3 (11.1) 7 (16.3) 0.5 4 (10.8) 6 (18.2) 0.64
N stage N0 19 (27.1) 6 (22.2) 13 (30.0) 10 (27.0) 9 (27.3)
N1 17 (24.3) 9 (33.3) 8 (18.6) 10 (27.0) 7 (21.2)
N2 13 (18.6) 7 (25.9) 6 (14.0) 10 (27.0) 3 (9.1)
N3 21 (30.0) 5 (18.6) 16 (37.4) 0.17 7 (19.0) 14 (42.4) 0.09
TNM stage I 5 (7.1) 0 () 5 (12.0) 2 (5.4) 3 (9.1)
II 26 (37.1) 13 (48.0) 13 (30.0) 16 (43.2) 10 (30.3)
III 39 (55.8) 14 (52.0) 25 (58.0) 0.10 19 (51.4) 20 (60.6) 0.5
ER  4 (5.7) 2 (7.4) 2 (4.7) 3 (8.1) 1 (3.1)
+ 18 (25.7) 6 (22.2) 12 (27.9) 7 (19) 11 (33.3)
++ 27 (38.6) 9 (33.3) 18 (41.9) 13 (35.1) 14 (42.4)
+++ 21 (30.0) 10 (37.1) 11 (25.6) 0.69 14 (37.8) 7 (21.2) 0.26
PR  11 (15.7) 3 (11.1) 8 (18.6) 3 (8.1) 8 (24.2)
+ 24 (34.3) 10 (37.1) 14 (32.6) 16 (43.2) 8 (24.2)
++ 14 (20.0) 6 (22.2) 8 (18.6) 7 (19.0) 7 (21.3)
+++ 21 (30.0) 8 (29.6) 13 (30.2) 0.85 11 (29.7) 10 (30.3) 0.19
HER2  57 (81.4) 26 (97.3) 31 (72.1) 34 (92.0) 23 (70.0)
+ 13 (18.6) 1 (2.7) 12 (27.9) 0.01 3 (8.0) 10 (30.0) 0.02
P53 <5% 50 (71.0) 21(77.8) 29 67.4) 28 (75.7) 22 (66.7)
P5% 20 (29.0) 6 (22.2) 14 (32.6) 0.42 9 (24.3) 11 (33.3) 0.44
SD: standard deviation, ER: estrogen receptors, HER2: Human Epidermal Growth factor receptor type 2. IDC: invasive duct carcinoma, IHC:
immunohisto-chemistry, ILC: invasive lobular carcinoma, NA: not applicable, PR: progesterone receptors.
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DFS was deﬁned as the time between the date of curative sur-
gery and date of ﬁrst relapse (local or distant) or death. OS was
deﬁned as the time between the date of diagnosis and date of
death or lost to follow up. Time to recurrence (TTR) was de-
ﬁned as the time between the date of curative surgery and date
of relapse. Early and late recurrences were deﬁned as relapse
within or more than 24 months from the start of adjuvant
tamoxifen, respectively.
Results
Patients’ characteristics and the corresponding Ki67 expression
The study included 70 patients with their characteristics shown
in Table 1. The mean age ± SD was 60 ± 5 years. Most pa-
tients had T2 tumors of IDC histology and grade II. The med-
ian tumor size was 30 mm (range, 15–105). The majority ofpatients had node-positive and TNM stage III disease. Only
13 patients (18.6%) had HER2 positive disease and hence
luminal B subtype. According to the study eligibility, all pa-
tients were hormone receptor (HR) positives (i.e. ER and/or
PR+) and had curative surgery being modiﬁed radical mastec-
tomy (MRM) in 89% of patients or breast conserving surgery
(CBS) in 11% of them. While none received neoadjuvant hor-
monal therapy, 12 patients (17%) received neoadjuvant
anthracycline-based chemotherapy; FAC in 7 patients and
FEC in 5 patients. While adjuvant radiotherapy was used in
76% of patients, adjuvant chemotherapy was used in 86% of
them; FAC in 39%, FEC in 36%, CMF in 10% and FEC-
docetaxel in 1%. None of the HER2 positive patients received
trastuzumab. All patients received adjuvant tamoxifen for a
median duration of 44 months (range, 9–60). The drug was
generally well tolerated with no serious adverse events
reported.
The median Ki67 value in the whole population was 22.5%
(range, 1%–90%). Apart from a signiﬁcantly higher Ki67 in
HER2 positive than HER2 negative tumors (median, 35%
Table 2 Comparison of characteristics of relapsed and non-relapsed breast cancer patients receiving adjuvant tamoxifen.
Characteristics No relapse
no. (%)
Relapse
no. (%)
p
Total 48 (100) 22 (100)
Age in years Mean ± SD 61 ± 5.0 59 ± 4.0 0.07
Histology IDC 42 (87.6) 20 (91.0)
ILC 3 (6.2) 2 (9.0)
mixed 3 (6.2) 0 (0) 0.46
Grade NA 3 (6.3) 2 (9.0)
IDC GII 41 (85.4) 18 (82.0)
IDC GIII 4 (8.3) 2 (9.0) 0.9
T stage T1 9 (18.8) 4 (18.0)
T2 28 (58.3) 9 (41.0)
T3 5 (10.4) 4 (18.0)
T4b 6 (12.5) 5 (23.0) 0.46
N stage N0 15 (31.2) 4 (18.0)
N1 14 (29.2) 3 (14.0)
N2 10 (20.8) 3 (14.0)
N3 9 (18.8) 12 (54.0) 0.03
TNM stage I 3 (6.0) 2 (9.0)
II 23 (48.0) 3 (14.0)
III 22 (46.0) 17 (77.0) 0.02
ER  3 (6.0) 1 (5.0)
+ 45 (96.0) 21 (95.0) 0.77
PR  8 (17.0) 3 (13.0)
+ 40 (83.0) 19 (87.0) 0.75
HER2/subtype* HER2/luminal A 41 (85.0) 16 (73.0)
HER2+/luminal B 7 (15.0) 6 (27.0) 0.21
Ki67 values <14% 23 (48.0) 4 (18.0)
14%–<30% 14 (29.0) 4 (18.0)
P30% 11 (23.0) 14 (64.0) 0.004
Ki67 (cut-oﬀ, 14%) Low (<14%) 23 (48.0) 4 (18.0)
High (P14%) 25 (52.0) 18 (82.0) 0.02
Ki67 (cut-oﬀ, 30%) Low (<30%) 37 (77.0) 8 (36.0)
High (P30%) 11 (23.0) 14 (64.0) <0.001
IDC: invasive duct carcinoma, ER: estrogen receptors, PR: progesterone receptors, HER2: Human Epidermal Growth factor receptor type 2,
IHC: immunohistochemistry, ILC: invasive lobular carcinoma, NA: not applicable.
* Ki67 was not considered in this subtyping.
184 H.M. Elzawahry et al.vs. 20%; range, 10%–80% vs. 1%–90%; p= 0.02), there were
no statistically signiﬁcant differences among various patients’
groups. Using a Ki67 cut-off value of 14% (Fig. 1), almost
39% and 61% of patients had low and high Ki67 expression,
respectively. Using the ROC curve method, the best cut-off
value of Ki67 that best predicts relapse in the current study
was 30% with a sensitivity of 73% and a speciﬁcity 65%,
(p= 0.004). Accordingly, about 53% and 47% of patients
had low and high Ki67 expression, respectively. HER2 positive
tumors were more likely to have Ki67 P14% or P30%
(p= 0.01 and 0.02, respectively; Table 1). Otherwise, Ki67
was not signiﬁcantly associated with other clinical and patho-
logical characteristics (Table 1).
Relapses and correlation with Ki67
At the last visit and with a median follow up period of
53 months (range, 34–70), 22/70 patients (31%) had evidenceof relapse. Relapses involved more than one site in 11/22 pa-
tients (50%). Relapses were distant in 21 patients (95.5%),
loco-regional in four patients (18.2%) or contralateral in one
patient (4.5%). Visceral metastases were the commonest affect-
ing 19/21 patients (90.5%). Sites of distant metastases were the
lungs/pleural effusion in 15 patients (71%), bone in 10 patients
(48%), liver in seven patients (33%), brain in two patients
(10%), ovaries in two patients (10%), and contra-lateral breast
in one patient (5%).
Ki67 was signiﬁcantly higher in patients with relapse (med-
ian, 45%; range, 5%–90%) compared to the non-relapsed
counterparts (median, 15%; range, 1%–90%; p= 0.003).
The median Ki67 was not signiﬁcantly different according to
the sites of relapse.
Compared to non-relapsed patients, patients who devel-
oped relapse tended to have higher N stage (p= 0.03), higher
TNM stages (p= 0.02) and lower survival rates (p< 0.001,
Table 2). Albeit statistically non-signiﬁcant, they tended to
Figure 1 Nuclear staining for Ki67 by immunohistochemistry (A: low ki67 & B: high Ki67).
Table 3 Luminal subtypes in 70 postmenopausal breast cancer patients receiving adjuvant tamoxifen with or without consideration of
Ki67.
Ki67 not considered Ki67 considered
LA
no. (%)
LB
no. (%)
p LA
no. (%)
LBH
no. (%)
LBH+
no. (%)
p
Total 57 (81.4) 13 (18.6) 26 (37.1) 31 (44.3) 13 (18.6)
Subtyping criteria
ER/PR + + + + +
HER2  +   +
Ki67 NC NC <14% P14% Any
Ki67: median(range) 20 (1–90) 35 (10–80) 0.02* 10 (1–12) 40 (15–90) 35 (10–80) <0.001*
<14% 26 (45.6) 1 (7.7) 26 (100) 0 1 (7.7)
14–29% 14 (24.6) 4 (30.8) 0 14 (45.2) 4 (30.8)
P30% 17 (29.8) 8 (61.5) 0.03 0 17 (54.8) 8 (61.5) <0.001
Relapse
No 41 (71.9) 7 (53.8) 22 (84.6) 19 (61.3) 7 (53.8)
Yes 16 (28.1) 6 (46.2) 0.15 4 (15.4) 12 (38.7) 6 (46.2) 0.08
LA: luminal A, LB: luminal B, LBH: luminal B/HER2 negative, LBH+: luminal B/HER2 positive, No: number, ER: estrogen receptors, PR:
progesterone receptors, HER2: Human Epidermal Growth factor receptor type 2, NC: not considered.
* Mann–Whitney Test was used to compare two groups and Kruskal–Wallis test to compare more than two groups.
Ki67 in postmenopausal luminal breast cancer 185be younger (p= 0.07) with higher T stages (p= 0.46) and to
have more HER2 positive tumors and subsequently luminal
B subtype (p= 0.21). Relapse was signiﬁcantly associated with
Ki67 with both of the used cut-offs (Table 2). Therapeutic
interventions (surgery, radiotherapy and chemotherapy) did
not differ signiﬁcantly between the two groups.
The median time to recurrence was 35 months (range, 17–
57). The median time from tamoxifen start to recurrence was
27 months (range, 9–49). Of the 22 relapses, 10 relapses were
encountered within (6) 24 months from tamoxifen start (early
relapses) and 12 relapses started >24 months from tamoxifen
start (late relapses). Comparison between patients with early
relapse and those with late relapse showed no signiﬁcant differ-
ences in patients’ clinical or pathological characteristics or
treatment patterns. Ki67 was signiﬁcantly higher in patients
with early relapse compared to the non-relapsed counterparts
(median, 53% vs. 20%, range, 5%–90% vs. 1%–90%,
p= 0.01). Patients with late relapse had a marginally higher
median Ki67 than the non-relapsed counterparts (median,
35% vs. 15%; range, 5%–85% vs. 1%–90%, p= 0.08). Themedian Ki67 was not signiﬁcantly different according to the
time of relapse.Breast cancer subtypes
Considering ER, PR and HER2, 57 tumors (81.4%) were clas-
siﬁed as luminal A (LA) and 13 tumors (18.6%) as LB (Ta-
ble 3). When Ki67 was additionally considered, 31 tumors
(44.3%) that were originally considered as LA had a ki67 value
P14% and were subtracted from LA (now became 26 tumors
[37.1%]) and added to LB and formed a new subcategory
called luminal B/HER2 (LBH) to differentiate it from the
luminal B/HER2+(LBH+) tumors (13 tumors [18.6%]).
Ki67 was signiﬁcantly higher in LB than in luminal A
(p= 0.02) and in LBH or LBH+ compared to A
(p= 0.001, for both comparisons). Ki67 was not signiﬁcantly
different between LBH and LBH+ (p= 0.99). Relapses oc-
curred in 46.2% of LB patients compared to 28.1% of LA pa-
tients (p= 0.15). When ki67 was considered in subtyping,
186 H.M. Elzawahry et al.relapses were 38.7% in LBH patients compared to 15.4% in
LA patients and 46.2% of LBH+ patients (p= 0.08).
Disease free survival (DFS)
The median DFS was not reached. The 2, 3 and 5 year DFS
rates for the whole group were 91%, 83% and 51% with a
standard error of the mean (SEM) of 3.3%, 4.6% and 9.4%,
respectively (Fig. 2A). DFS was signiﬁcantly correlated with
TNM stage (p= 0.03, Fig. 3A) and intensity of ER expression
(p= 0.02, Fig. 3B). The 3- and 5- years DFS in patients with a
Ki67 <14% were 96% and 76%, respectively, and in those
with Ki67 P14% they were 77% and 46%, respectively,
(p= 0.046, Fig. 4A). The 3- and 5- years DFS in patients with
a Ki67 <30% were 97% and 67%, respectively, and in those
with Ki67 P30% they were 70% and 49%, respectively,
(p= 0.001, Fig. 4B).
There was no signiﬁcant difference in DFS among different
luminal subtypes (p= 0.08, Fig. 5A). For LA subtype, the 3-
and 5- year DFS rates were 96% and 75%, respectively. ForFigure 2 Disease-free survival (DFS; panel A) and overall survival (O
adjuvant tamoxifen.
Figure 3 Disease-free survival (DFS) in 70 postmenopausal breast can
and (panel A) and Estrogen receptor expression (panel B). ER(): ER nLBH subtype, the 3- and 5- year DFS rates were 81% and
57%, respectively. For LBH+ subtype, the 3- and 5- year
DFS rates were 70% and 0%, respectively. Also, there were
no signiﬁcant differences in DFS among different histologic
subtypes (p= 0.64), grades (p= 0.79), T stages (p= 0.59),
N stages (p= 0.08), PR expression (p= 0.98), HER2+ and
HER2 patients (p= 0.06), those who received or did not re-
ceive neoadjuvant chemotherapy (NACT; p= 0.54), adjuvant
chemotherapy (ACT; p= 0.4), adjuvant radiation therapy
(p= 0.2) or BCS and MRM (p= 0.65).Overall survival (OS)
At the last visit, 58 patients were alive and 12 were dead; 10
with evidence of relapse and two without such evidence. The
median OS was not reached for the whole group or any sub-
type. The 3- and 5- year OS rates for the whole group were
98% and 77% with SEM of 1.5% and 6.2%, respectively
(Fig. 2B).S; panel B) in 70 postmenopausal breast cancer patients receiving
cer patients receiving adjuvant tamoxifen according to TNM stage
egative, ER(+, ++, +++): increasing degrees of ER positivity.
Figure 4 Disease-free survival (DFS) in 70 postmenopausal breast cancer patients receiving adjuvant tamoxifen according to Ki67 level
(Panel A: Ki <14% or P14%, Panel B: Ki <30% or P30%).
Figure 5 Disease-free survival (DFS; panel A) and overall survival (OS; panel A) in 70 postmenopausal breast cancer patients receiving
adjuvant tamoxifen according to luminal subtype.
Ki67 in postmenopausal luminal breast cancer 187The 3- and 5- years OS in patients with a Ki67 <14%
were 100% and 90% and in those with Ki67 P14% were
98% and 70% (p= 0.14, Fig. 6A). The 3- and 5- years OS
in patients with a Ki67 <30% were 100% and 93% and in
those with Ki67 P30% were 97% and 60% (p= 0.007,
Fig. 6B). There was no statistical difference in OS among
different subtypes (p= 0.22, Fig. 5B). For LA subtype, the
3- and 5-year OS rates were 100% and 90%, respectively.
For LBH subtype, the 3- and 5-year OS rates were 97%
and 75%, respectively. For LBH+ subtype, the 3- and 5-year
OS rates were 92% and 60%, respectively. Also, there were
no signiﬁcant differences in OS among different histologic
subtypes (p= 0.71), grades (p= 0.97), T stages (p= 0.34),
N stages (p= 0.29), TNM stages (p= 0.17), among different
ER or PR expression (p= 0.08 and 0.90, respectively),
among HER2+ and HER2 patients (p= 0.14), those
who received or did not receive NACT (p= 0.18), ACT
(p= 0.18), adjuvant radiation therapy (p= 0.5), or between
MRM and BCS (p= 0.68).Multivariate analysis
Using cox regression analysis to detect independent variables
(covariates) affecting DFS and OS; variables that were signif-
icantly related to outcome in univariate analysis or had bor-
derline signiﬁcance were involved in two models. Model 1
(Ki67 <14% or P14%) revealed non-signiﬁcance. Whereas
in model 2 (Ki67 <30% or P30%), Ki values P30% raises
the likelihood of recurrence about 4 times as compared to
Ki67 values <30% (HR= 3.7; CI 95%, 1.4–9.6; p= 0.007).
Also TNM stage III as compared to stage I & II raises the like-
lihood of recurrence to about 3 times (HR= 2.6; CI 95%,
0.97–7.2; p= 0.057).Discussion
Compared to no treatment, adjuvant tamoxifen for 5 years in
hormone receptor positive reduced the annual BC recurrence
Figure 6 Overall survival (OS) in 70 postmenopausal breast cancer patients receiving adjuvant tamoxifen according to Ki67 level (Panel
A: Ki <14% or P14%, Panel B: Ki <30% or P30%).
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motherapy, age or other tumor characteristics [9]. The data of
adjuvant tamoxifen were recently announced. Compared to
5 years, 10 years of tamoxifen further reduced BC recurrence,
BC mortality and all-cause mortality by 13%, 17% and
11%, respectively. By 15 years, BC recurrences decreased from
25% to 21% and BC mortality from 15% to 12% [30].
In their review article, Ring and Dowsett [10] mentioned
that up to 40% of patients receiving adjuvant tamoxifen will
eventually relapse and die from their disease. In the current
study and after a median follow up of 53 months, 31% of
the patients relapsed while receiving adjuvant tamoxifen.
Distant, locoregional and contralateral relapses were docu-
mented in 30%, 5.7% and 1.4%, respectively compared to
8.6%, 2.1% and 1.1%, respectively in the BIG1-98 trial
[20]. This may be explained by the higher tumor grades
and the more advanced disease as evidenced by larger tumor
size and more involvement of the axillary lymph nodes for
patients in the current study compared to the mentioned
study.
Saphner et al. [31] reported that the risk of recurrence of BC
is higher in the ﬁrst 5 years after diagnosis, but with the highest
peak within 2–3 years of diagnosis, independent of nodal and
hormone receptor status. In the current study, the earliest
recurrence occurred 18 months from diagnosis and 17 months
from the date of curative surgery. All patients received adju-
vant tamoxifen for a median duration of 44 months and the
median time from tamoxifen start to recurrence was
27 months. Todorovic-Rakovic et al. [32] found that, hyper-
activated HER2 signaling network results in activation of the
non-genomic pathway of ER via hyper-stimulation of the
MAPK/Erk pathway that results in down-regulation of ER
leading to generation of the ER-negative phenotype and ﬁnal-
ly, tamoxifen resistance. In agreement with this theory; 46% of
the patients who were positive for HER2 in the current study
developed recurrence despite receiving adjuvant tamoxifen.
This could be explained by the combined effects of HER2
overexpression, high Ki67 and the complete absence of treat-
ment with anti-HER2 therapy, all these factors increased the
risk of relapse in this group. We showed a signiﬁcant associa-
tion between HER2 overexpression and Ki67 score (p= 0.02).Thus, possible explanations for the relation between high Ki67
score and the development of tamoxifen resistance can be due
to increased expression of HER2 associated genes and a cell
proliferation signature that includes the expression of MKI67,
CCNB1, and MYBL2, which has been associated with tamox-
ifen resistance in the studies done by Marcom et al. [33] and
Oh et al. [34].
BC is no longer considered as a single disease, subtypes can
be deﬁned by genetic array testing or approximations to this
classiﬁcation using IHC [35]. By gene expression proﬁling, Sørlie
et al. [36] had identiﬁed two biologically distinct ER-positive
subtypes of BC: luminal A (LA) with negativity for HER2 and
luminal B (LB) with HER2 overexpression. The latter also has
more proliferation and poorer prognosis than the former.Going
with this classiﬁcation; 81% of the patients in the current study
was LA and 19% was LB. The latter had worse prognosis as
46% of this group developed relapse compared to 28% of the
LA group. Similar to the results reported by Viale et al. [23]
and Nishimura et al. [37], Ki67 expression in the current study
was signiﬁcantly higher in HER2 positive (i.e. LB) compared
to HER2 negative (i.e. LA) tumors (p= 0.02).
After the results of the meta-analysis on 12155 patients
done by de Azambuja et al. [18] had revealed that high Ki67
positivity conferred a higher risk of relapse and a worse sur-
vival in patients with early BC; Cheang et al. [28] further clas-
siﬁed the luminal tumors by the use of IHC for ER, PR, HER2
and Ki67. They used a cut-off value of 14% for Ki67 to assign
tumors into LA (Ki67 <14% and HER2 negative), LB/HER2
negative (Ki67 P14% with HER2 negativity) and LB/HER2
positive (any Ki67 and HER2 overexpression). This cut-off va-
lue was subsequently accepted by the St. Gallen 2011 Breast
Cancer Conference [35]. Applying this classiﬁcation to the cur-
rent study; 37%, 44% and 19% of the patients were assigned
to LA, LB/HER2 negative (LBH) and LB/HER2 positive
(LBH+), respectively. The latter represented 30% of all
LB patients and this is similar to what reported by Perou
et al. [38] and Hu et al. [39]. Ki67 expression was statistically
signiﬁcantly different among these groups (p< 0.001).
Regarding prognosis for these luminal subtypes in the cur-
rent study; 15%, 39% and 46% of the patients in the LA,
LBH and LBH+ developed relapse, respectively, but this
Ki67 in postmenopausal luminal breast cancer 189was statistically non-signiﬁcant (p= 0.08). We believe that if
our sample was larger, this ﬁnding could have reached the level
of statistical signiﬁcance. These ﬁndings collectively conﬁrm
the impact of Ki67 as a proliferation marker on the biological
behavior of the tumor and that Ki67 identiﬁes a subgroup of
patients originally allocated to LA and has a poor prognosis
similar to LB.
In the current study, themedianKi67 valuewas 22.5% (IQR,
10%–50%). This is similar to the median of 20.0%–22.7%men-
tioned by other investigators [37,40]. However, it is higher than
12% that was mentioned by Viale et al. [41]. Despite that pa-
tients in the latter study were similar to ours – postmenopausal
with amedian age of 61 years- they presentedwith less advanced
tumors (T1 in 63% vs. 19% in the current study), less nodal
involvement (N0 in 58% vs. 27%), more grade I tumors (28%
vs. 0%) and less HER2 over-expression (6% vs. 19%).
The best Ki67 cut-off value in the current study that pre-
dicts relapse was 30%. This is higher than most of the reported
cut-off values in recent BC studies that ranged between 10%
and 20% [21–23,28,37,41,42]. The higher Ki67 value that pre-
dicted relapse in our study might be due to limiting inclusion
only to postmenopausal patients with luminal subtype in con-
trast to most of the other studies that included premenopausal
as well as postmenopausal patients and were not restricted to
the luminal subtype.
Ki67 in the current study was not signiﬁcantly different
among histologic subtypes, grades, different TNM stages. This
may reﬂect the importance of Ki67 as an indicator of tumor
biology and aggressiveness rather than tumor stage that is lia-
ble to be upgraded with a lack of awareness and underdevel-
oped health care systems. However, Viale et al. [23] and
Nishimura et al. [37] reported contradictory ﬁndings. Sampling
variability with lower grade and stage tumors could be a rea-
son for these differences.
High Ki67 was signiﬁcantly correlated with poor DFS in the
current study, in agreement with what many previous reports
[18,21,23,28,37,42]. These ﬁndings were also subsequently con-
ﬁrmed on multivariate analysis that revealed that Ki67P30%
was an independent prognostic factor raising the likelihood of
recurrence about 4 times as compared to Ki67 <30%. High
Ki67 (P30%) inferred worse OS compared to low (<14%) or
intermediate levels (14%–29%) (p= 0.007). These results are
also similar to those reported by de Azambuja et al. [18], Guar-
neri et al. [42] and Nishimura et al. [37].
In the current study, Ki67 was signiﬁcantly higher in pa-
tients who relapsed in 624 months from tamoxifen start com-
pared to those without relapse in the same period (p= 0.007).
This signiﬁcant ﬁnding was not found in the comparison be-
tween patients who developed relapse >24 month from
tamoxifen start and those who were free of recurrence in the
same period (p= 0.2). This result might give a clue to that,
postmenopausal patients with tumors expressing high Ki67
score may develop early resistance to tamoxifen and conse-
quently, develop early relapse. Similar to our results; patients
in BIG1–98 study with high Ki67 received tamoxifen had a
hazard ratio for a DFS event that was about double that of pa-
tients who received letrozole. Despite this ﬁnding was not sta-
tistically signiﬁcant (p= 0.09), the authors concluded that
high Ki67 might identify a group of patients that can beneﬁt
from initial adjuvant letrozole [20]. Based also on this, aro-
matse inhibitors might be the preferred initial adjuvant hor-
monal therapy in this subgroup of patients [31].Conclusions and recommendations
Unfortunately, Egyptian postmenopausal BC patients present
with an advanced disease where aggressive therapies are man-
dated with an overall less favorable outcome. Increasing
awareness among patients and health care professionals and
adoption of screening may lead to earlier diagnosis with a bet-
ter outcome. Neoadjuvant therapies and adjuvant taxanes
were infrequent in the current study. Health education may en-
sure best use of such treatment modalities. Ki67 must be incor-
porated in the recurrence and mortality risk models that guide
adjuvant chemo and hormonal therapies. We strongly recom-
mend the universal adoption of the IHC4 panel (ER, PR,
HER2, Ki67) in the initial assessment of any BC. We believe
that the incremental cost of adding Ki67 to the triple-receptor
panel is small but worthy. Management of BC in the adjuvant
setting should be molecular subtype-oriented e.g. chemother-
apy (particularly including taxanes) and aromatase inhibitors
have to be offered in the adjuvant setting when dealing with
luminal B postmenopausal BC patients. HER2+ patients
should receive adjuvant trastuzumab. Luminal A patients are
less responsive to chemotherapy and hormonal therapy in
the form of tamoxifen or aromatase inhibitors may be the
adjuvant treatment modality of choice.
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